BioCryst Pharmaceuticals Inc
BCRXBioCryst Pharmaceuticals Inc. is a biotechnology company focused on discovering, developing, and commercializing specialty pharmaceuticals for the treatment of rare and infectious diseases. The company primarily develops oral medicines that inhibit specific enzymes involved in disease processes, with a key focus on antiviral and immune modulatory therapies.
Company News
BioCryst Pharmaceuticals completed its $700 million acquisition of Astria Therapeutics, adding navenibart, a late-stage plasma kallikrein inhibitor in Phase 3 development for hereditary angioedema (HAE). The acquisition strengthens BioCryst's HAE portfolio alongside its leading oral therapy ORLADEYO, with navenibart potentially offering every-thr...
Law firm investigating potential securities law violations and fiduciary duty breaches for multiple companies involving merger and acquisition transactions.
BioCryst will present four abstracts at the ACAAI Annual Scientific Meeting, focusing on pediatric hereditary angioedema (HAE) research, including long-term prophylaxis data for ORLADEYO in children aged 2 to <12 years and psychosocial impact studies.
BioCryst Pharmaceuticals announced it will acquire Astria Therapeutics for $700 million, adding a new product candidate (Navenibart) for hereditary angioedema treatment, with the deal expected to close in Q1 2026.
BioCryst Pharmaceuticals granted stock options and restricted stock units to eight newly-hired employees, covering 115,000 shares and 91,450 shares respectively, as part of their employment inducement strategy.
